Barry D. Quart's most recent trade in Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A was a trade of 12,336 Share Option done . Disclosure was reported to the exchange on June 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 12,336 | 0 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Sale of securities on an exchange or to another person at price $ 30.39 per share. | 09 Jun 2025 | 12,336 | 12,546 (0%) | 0% | 30.4 | 374,891 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.80 per share. | 09 Jun 2025 | 12,336 | 24,882 (0%) | 0% | 3.8 | 46,877 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 8,212 | 12,336 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Sale of securities on an exchange or to another person at price $ 30.36 per share. | 09 Jun 2025 | 8,212 | 12,546 (0%) | 0% | 30.4 | 249,316 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.80 per share. | 09 Jun 2025 | 8,212 | 20,758 (0%) | 0% | 3.8 | 31,206 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.80 per share. | 09 Jun 2025 | 6,900 | 19,446 (0%) | 0% | 3.8 | 26,220 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 6,900 | 20,548 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Sale of securities on an exchange or to another person at price $ 30.26 per share. | 09 Jun 2025 | 6,900 | 12,546 (0%) | 0% | 30.3 | 208,794 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 16,798 | 16,798 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2025 | 3,173 | 12,546 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2025 | 3,173 | 0 | - | - | Restricted Share Units | |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 2,799 | 2,799 | - | - | Restricted Share Units | |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 19,040 | 19,040 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2024 | 4,373 | 0 | - | - | Restricted Share Units | |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2024 | 4,373 | 9,373 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 3,173 | 3,173 | - | - | Restricted Share Units | |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2023 | 5,000 | 0 | - | - | Restricted Share Units | |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2023 | 5,000 | 5,000 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 26,236 | 26,236 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 4,373 | 4,373 | - | - | Restricted Share Units | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2023 | 850,000 | 850,000 | - | - | Employee Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 16,122 | 114,807 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 16,122 | 183,208 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.17 per share. | 13 Jan 2023 | 5,219 | 177,989 (0%) | 0% | 3.2 | 16,544 | Common Stock |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 3,645 | 167,086 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 3,645 | 25,521 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Other type of transaction at price $ 3.27 per share. | 13 Jan 2023 | 1,655 | 163,441 (0%) | 0% | 3.3 | 5,416 | Common Stock |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2022 | 21,959 | 0 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Sale of securities on an exchange or to another person at price $ 16.15 per share. | 29 Nov 2022 | 21,959 | 0 (0%) | 0% | 16.2 | 354,638 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 29 Nov 2022 | 21,959 | 21,959 (0%) | 0% | 1.6 | 34,915 | Class A Common Share |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 16,122 | 167,005 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 16,122 | 130,929 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.76 per share. | 13 Oct 2022 | 5,219 | 161,786 (0%) | 0% | 3.8 | 19,623 | Common Stock |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 3,646 | 29,166 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 3,646 | 150,883 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 16,122 | 147,051 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 16,122 | 152,456 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.01 per share. | 13 Jul 2022 | 5,219 | 147,237 (0%) | 0% | 3.0 | 15,709 | Common Stock |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 3,646 | 32,812 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 3,646 | 136,334 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Other type of transaction at price $ 3.84 per share. | 13 Jul 2022 | 1,504 | 132,688 (0%) | 0% | 3.8 | 5,778 | Common Stock |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2022 | 30,000 | 30,000 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2022 | 5,000 | 5,000 | - | - | Restricted Share Units | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 16,122 | 163,173 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 16,122 | 136,403 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.07 per share. | 13 Apr 2022 | 5,219 | 131,184 (0%) | 0% | 6.1 | 31,679 | Common Stock |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 3,646 | 120,281 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 3,646 | 36,458 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 16,122 | 179,295 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 16,122 | 121,854 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.30 per share. | 13 Jan 2022 | 5,219 | 116,635 (0%) | 0% | 8.3 | 43,318 | Common Stock |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 3,646 | 105,732 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 3,646 | 40,104 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2021 | 390,834 | 390,834 | - | - | Employee Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2021 | 195,417 | 195,417 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2021 | 3,646 | 103,049 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2021 | 3,646 | 43,750 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.55 per share. | 13 Oct 2021 | 963 | 102,086 (0%) | 0% | 10.6 | 10,160 | Common Stock |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2021 | 3,645 | 100,366 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2021 | 3,645 | 47,396 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Other type of transaction at price $ 13.90 per share. | 13 Jul 2021 | 1,529 | 96,721 (0%) | 0% | 13.9 | 21,249 | Common Stock |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.48 per share. | 13 Jul 2021 | 963 | 99,403 (0%) | 0% | 13.5 | 12,981 | Common Stock |
| Kiniksa Pharmaceuticals Lt... | Barry D. Quart | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 33,237 | 33,237 | - | - | Share Option | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 3,646 | 92,872 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 3,646 | 54,687 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.16 per share. | 13 Jan 2021 | 963 | 91,909 (0%) | 0% | 18.2 | 17,488 | Common Stock |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2020 | 350,000 | 350,000 | - | - | Employee Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2020 | 58,333 | 58,333 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Barry D. Quart | Director, Chief Executive Officer | Other type of transaction at price $ 12.12 per share. | 13 Oct 2020 | 1,158 | 89,226 (0%) | 0% | 12.1 | 14,036 | Common Stock |